$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000115903615000079 Filed on August 10, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$33.34M	$18.39M
YoY Change	81.32%	27.2%
Cost Of Revenue	$8.144M	$5.924M
YoY Change	37.47%	361.37%
Gross Profit	$5.391M	$3.570M
YoY Change	51.01%	96.59%
Gross Profit Margin	16.17%	19.42%
Selling, General & Admin	$9.814M	$8.752M
YoY Change	12.13%	19.89%
% of Gross Profit	182.04%	245.15%
Research & Development	$21.20M	$18.65M
YoY Change	13.65%	-33.38%
% of Gross Profit	393.16%	522.38%
Depreciation & Amortization	$400.0K	$400.0K
YoY Change	0.0%	33.33%
% of Gross Profit	7.42%	11.2%
Operating Expenses	$31.01M	$27.40M
YoY Change	13.17%	-22.36%
Operating Profit	$4.231M	-$14.94M
YoY Change	-128.32%	-32.46%
Interest Expense	$1.299M	$1.451M
YoY Change	-10.48%	70.91%
% of Operating Profit	30.7%
Other Income/Expense, Net	$87.00K	$118.0K
YoY Change	-26.27%	103.45%
Pretax Income	$3.019M	-$16.30M
YoY Change	-118.52%	-28.82%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	-$26.88M	-$16.27M
YoY Change	65.15%	-28.98%
Net Earnings / Revenue	-80.62%	-88.51%
Basic Earnings Per Share	$0.02	-$0.13
Diluted Earnings Per Share	$0.02	-$0.13
COMMON SHARES
Basic Shares Outstanding	126.1M shares	123.7M shares
Diluted Shares Outstanding	134.5M shares	123.7M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$140.7M	$147.6M
YoY Change	-4.67%	94.21%
Cash & Equivalents	$67.77M	$56.14M
Short-Term Investments	$72.90M	$91.50M
Other Short-Term Assets	$10.30M	$8.000M
YoY Change	28.75%	-27.93%
Inventory	$7.723M	$7.114M
Prepaid Expenses
Receivables	$9.738M	$12.90M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$168.4M	$175.6M
YoY Change	-4.09%	74.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.594M	$3.343M
YoY Change	-22.41%	-26.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.000M	$3.100M
YoY Change	-3.23%	29.17%
Total Long-Term Assets	$5.605M	$6.429M
YoY Change	-12.82%	-7.72%
TOTAL ASSETS
Total Short-Term Assets	$168.4M	$175.6M
Total Long-Term Assets	$5.605M	$6.429M
Total Assets	$174.0M	$182.1M
YoY Change	-4.4%	69.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.138M	$3.910M
YoY Change	5.83%	-47.73%
Accrued Expenses	$14.82M	$16.46M
YoY Change	-9.93%	7.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.656M	$6.203M
YoY Change	55.67%	70.26%
Total Short-Term Liabilities	$35.04M	$31.72M
YoY Change	10.46%	-3.39%
LONG-TERM LIABILITIES
Long-Term Debt	$40.10M	$43.60M
YoY Change	-8.03%	54.61%
Other Long-Term Liabilities	$3.429M	$2.854M
YoY Change	20.15%	320.51%
Total Long-Term Liabilities	$3.429M	$2.854M
YoY Change	20.15%	320.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.04M	$31.72M
Total Long-Term Liabilities	$3.429M	$2.854M
Total Liabilities	$38.47M	$34.58M
YoY Change	11.26%	3.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$462.5M	-$424.9M
YoY Change	8.86%	24.68%
Common Stock	$512.8M	$480.2M
YoY Change	6.79%	36.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.23M	$55.30M
YoY Change
Total Liabilities & Shareholders Equity	$174.0M	$182.1M
YoY Change	-4.4%	69.53%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$26.88M	-$16.27M
YoY Change	65.15%	-28.98%
Depreciation, Depletion And Amortization	$400.0K	$400.0K
YoY Change	0.0%	33.33%
Cash From Operating Activities	$8.900M	-$15.80M
YoY Change	-156.33%	44.95%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$400.0K
YoY Change	-25.0%	300.0%
Acquisitions
YoY Change
Other Investing Activities	$11.00M	-$5.500M
YoY Change	-300.0%
Cash From Investing Activities	$10.80M	-$5.900M
YoY Change	-283.05%	5800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.700M	1.200M
YoY Change	208.33%
NET CHANGE
Cash From Operating Activities	8.900M	-15.80M
Cash From Investing Activities	10.80M	-5.900M
Cash From Financing Activities	3.700M	1.200M
Net Change In Cash	23.40M	-20.50M
YoY Change	-214.15%	86.36%
FREE CASH FLOW
Cash From Operating Activities	$8.900M	-$15.80M
Capital Expenditures	-$300.0K	-$400.0K
Free Cash Flow	$9.200M	-$15.40M
YoY Change	-159.74%	42.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12771772	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC.
CY2014Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	1266000	USD
CY2015Q2	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	581000	USD
CY2014Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2133000	USD
CY2015Q2	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2291000	USD
CY2014Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	6361000	USD
CY2015Q2	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	7692000	USD
CY2014Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4383000	USD
CY2015Q2	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4917000	USD
CY2014Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	480000	USD
CY2015Q2	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	593000	USD
CY2014Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2112000	USD
CY2015Q2	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2430000	USD
CY2015Q2	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	55000000	USD
CY2015Q2	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2014Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	611000	USD
CY2015Q2	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	826000	USD
CY2014Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	6339000	USD
CY2015Q2	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	7145000	USD
CY2014Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2380000	USD
CY2015Q2	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3529000	USD
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3003000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4138000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9760000	USD
CY2015Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	10564000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	944000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1317000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	52000	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-131000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-772000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1436000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9149000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9738000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-687000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-548000	USD
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14441000	USD
CY2015Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	15414000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13961000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14821000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9219000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9916000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	491694000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	512657000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3594000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6889000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5905000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10035000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1178000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	528000	USD
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9800000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9800000	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9200000	shares
CY2014Q4	us-gaap	Assets Assets	165977000	USD
CY2015Q2	us-gaap	Assets Assets	174047000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	161321000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	168442000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	116919000	USD
CY2015Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	133282000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	74234000	USD
CY2015Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	72946000	USD
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	72900000	USD
CY2015Q2	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	24
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56135000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61389000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67769000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	28778000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6380000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125721000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	127764000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125721000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	127764000	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	126000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	128000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16245000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42835000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3006000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12088000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5924000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11444000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8144000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	14638000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	33325000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	70510000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	39153000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	71730000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	54634000	USD
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	51676000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7367000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6424000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	47267000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45252000	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	USD
CY2015Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	840000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	816000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5923000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4881000	USD
CY2014Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3174000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1691000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3798000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	589000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	575000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2957000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	1451000	USD
	us-gaap	Interest Expense InterestExpense	2827000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	1299000	USD
	us-gaap	Interest Expense InterestExpense	2598000	USD
CY2014Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1500000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2800000	USD
CY2015Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1300000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2600000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	646000	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1090000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	6406000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	7723000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	553000	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	144000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5207000	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	6489000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165977000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174047000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24331000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	35039000	USD
CY2014Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	7203000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	9802000	USD
CY2015Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	24660000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	26691000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	49860000	USD
CY2015Q2	us-gaap	Long Term Debt LongTermDebt	40098000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	9656000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111235000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10930000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49061000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	351000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33396000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4901000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-16273000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42821000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	3019000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12089000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14940000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40159000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	4231000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9680000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2023000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3186000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2000000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	1535000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2600000	USD
CY2015Q2	us-gaap	Other Assets OtherAssets	599000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	28000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3167000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3429000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	118000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	165000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	87000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	189000	USD
CY2014Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1094000	USD
CY2015Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1504000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	89116000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	33184000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	761000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	390000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11348000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	12777000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10143000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10266000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1205000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2511000	USD
CY2015Q2	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3522000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10930000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	40816000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33925000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12170000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12510000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2951000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2594000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18649000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40064000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21195000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37879000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2015Q1	us-gaap	Restructuring And Related Cost Description RestructuringAndRelatedCostDescription	paid in full
CY2014Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2014Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	500000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450427000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-462516000	USD
CY2014Q2	us-gaap	Revenues Revenues	18385000	USD
	us-gaap	Revenues Revenues	30351000	USD
CY2015Q2	us-gaap	Revenues Revenues	43384000	USD
	us-gaap	Revenues Revenues	62050000	USD
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1688000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	2487000	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	6382000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	13157000	USD
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9494000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	18062000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12342000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	22202000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8752000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19002000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9814000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19213000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6889000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10035000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.711
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.710
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.668
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.667
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	200000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2100000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	900000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7200000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8300000	shares
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41352000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	50229000	USD
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2015Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	8363000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123710000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121200000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134507000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125723000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123710000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121200000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126144000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125723000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is seeking to translate our unique knowledge of the tumor microenvironment to create novel therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (“HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as Enhanze</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> technology. rHuPH20 is also the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. When HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 works by temporarily degrading HA surrounding some cancer cells and results in reduced pressure and increased blood flow to the cancer with increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 clinical testing for PEGPH20 in metastatic pancreatic cancer (Study 109-202) and in Phase 1b clinical testing in non-small cell lung cancer (Study 107-201).</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regarding Enhanze, we currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxter Healthcare Corporation (predecessor to Baxalta Incorporated) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), and AbbVie, Inc. (“AbbVie”), with one product approved in the U.S. and three products approved for marketing in Europe from which we are receiving royalties and several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.'s wholly owned subsidiary, Halozyme Holdings Ltd.</font></div></div>

Files In Submission

Name	View Source	Status
0001159036-15-000079-index-headers.html	Edgar Link	pending
0001159036-15-000079-index.html	Edgar Link	pending
0001159036-15-000079.txt	Edgar Link	pending
0001159036-15-000079-xbrl.zip	Edgar Link	pending
ex101amendedandrestated201.htm	Edgar Link	pending
ex102formofrsuagreement.htm	Edgar Link	pending
ex103rsaagreement.htm	Edgar Link	pending
ex311q22015.htm	Edgar Link	pending
ex312q22015.htm	Edgar Link	pending
ex32q22015.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
halo-20150630.xml	Edgar Link	completed
halo-20150630.xsd	Edgar Link	pending
halo-20150630_cal.xml	Edgar Link	unprocessable
halo-20150630_def.xml	Edgar Link	unprocessable
halo-20150630_lab.xml	Edgar Link	unprocessable
halo-20150630_pre.xml	Edgar Link	unprocessable
halo2q2015-10q.htm	Edgar Link	pending
pipelineslide28july2015a04.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2015 Q2 Form 10-Q Financial Statement

#000115903615000079 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2015 Q2 Form 10-Q Financial Statement

#000115903615000079 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo